BIOGEN INC.

BIIB · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances) · Market Cap: $25.3B · 7,500 employees
179
SEC Filings
$172.97
Close 2026-04-10
7,500
Employees

Business Summary

Biogen Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies for neurological and other serious diseases. Key marketed products include LEQEMBI (Alzheimer's disease), SKYCLARYS (Friedreich's ataxia), and TYSABRI. The company also develops biosimilars and has a pipeline including felzartamab, litifilimab, and salanersen, with collaborations with partners such as Eisai and Supernus.

Latest Stock Quote

BIIB 2026-04-10 $172.97 O:$177.97 H:$177.97 L:$172.32 Vol:1.5M VWAP:$173.4039
origin leaf: 5af0eb5646329a1816fddd0423752d885d8cad458e15c83803d35e02ca50b488

Next Earnings

expected 2026-07-13

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionBIIBdiscussed_in_filing Sovereign & Government
topic_mentionBIIBdiscussed_in_filing Sovereign & Government
topic_mentionBIIBdiscussed_in_filing Sovereign & Government
topic_mentionBIIBdiscussed_in_filing Sovereign & Government

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-02-062025-12-310000875045-26-000013EDGAR110K words
2025-02-122024-12-310000875045-25-000009EDGAR—
2024-02-142023-12-310000875045-24-000009EDGAR—
2023-02-152022-12-310000875045-23-000009EDGAR—
2022-02-032021-12-310000875045-22-000007EDGAR—
2021-02-032020-12-310000875045-21-000010EDGAR—
2020-02-062019-12-310000875045-20-000005EDGAR—
2019-02-062018-12-310000875045-19-000006EDGAR—
2018-02-012017-12-310000875045-18-000005EDGAR—
2017-02-022016-12-310000875045-17-000009EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-10-302025-09-300000875045-25-000049EDGAR60K words
2025-07-312025-06-300000875045-25-000033EDGAR—
2025-05-012025-03-310000875045-25-000018EDGAR—
2024-10-302024-09-300000875045-24-000032EDGAR—
2024-08-012024-06-300000875045-24-000025EDGAR—
2024-04-242024-03-310000875045-24-000016EDGAR—
2023-11-082023-09-300000875045-23-000038EDGAR—
2023-07-252023-06-300000875045-23-000030EDGAR—
2023-04-252023-03-310000875045-23-000016EDGAR—
2022-10-252022-09-300000875045-22-000031EDGAR—
2022-07-202022-06-300000875045-22-000025EDGAR—
2022-05-032022-03-310000875045-22-000016EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-04-060000875045-26-000039EDGAR1K words
2026-03-310001193125-26-134889EDGAR—
2026-03-110000950157-26-000280EDGAR—
2026-02-110001193125-26-046803EDGAR—
2026-02-060000875045-26-000011EDGAR—
2026-01-140000875045-26-000003EDGAR—
2025-10-300000875045-25-000047EDGAR—
2025-10-140000875045-25-000040EDGAR—
2025-07-310000875045-25-000035EDGAR—
2025-07-070000875045-25-000027EDGAR—

179 total filings indexed. 147 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Tags

neurology rare-diseases biosimilars biopharmaceuticals

Company Identity

CIK0000875045
TickerBIIB
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE
Websitehttps://www.biogen.com
Listed1991-09-17

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: b9621ca7e509c9c839e3f5719cab556ab8356684a3ca526903b7967d5f2e15c0
parent: 501e45abe83ac2244d697a884c8f7a96ea681a7b85bf49abf3e7647caf7371fc
content hash: f5d452be0e5158355a960617bc909dee554b7e9998438f3bbd7983fea113889d
signed: 2026-04-13T04:43:58.048Z
sources: 23 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf